MetaCap

Werewolf Therapeutics (HOWL) vs Heron Therapeutics (HRTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Werewolf Therapeutics (HOWL) has outperformed Heron Therapeutics (HRTX) over the past year, gaining 8.4% versus a loss of 76.2%. Over five years, HOWL leads with a -93.7% price change compared with -97.3% for HRTX. Heron Therapeutics is the larger company by market cap ($48.0 million vs $46.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HOWL+8.43%HRTX-76.18%
+46%-18%-82%
Nov 21, 20251 yearNov 20, 2026
HOWL-94.08%HRTX-97.51%
+5%-49%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HOWL versus HRTX key metrics
MetricHOWLHRTX
Share price$0.9466$0.2525
Market cap$46.00M$48.04M
1-day change-3.97%-4.39%
YTD return+49.31%-80.58%
1-year return+8.43%-76.18%
5-year return-93.68%-97.32%
EPS (TTM)$-0.58$-0.11
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$154.90M
Revenue growth (YoY)—+7.36%
Net income (latest FY)$-60.82M$-20.20M
Gross margin—73.31%
Operating margin—-1.64%
Net margin—-13.04%
52-week high$1.20$1.58
52-week low$0.27$0.2479
Distance from 52-week high-21.12%-84.02%
Analyst consensusnonenone
Avg. price target upside+639.49%+2672.28%
Average volume1.08M4.56M
Shares outstanding48.60M190.27M
Employees39128
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • HOWL has outperformed HRTX by 84.6 percentage points over the past year.

About Werewolf Therapeutics

HOWL stock →

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.

Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees

About Heron Therapeutics

HRTX stock →

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees

HOWL vs HRTX FAQ

Which is bigger, Werewolf Therapeutics or Heron Therapeutics?

Heron Therapeutics (HRTX) is larger, with a market capitalization of $48.04M compared with $46.00M for Werewolf Therapeutics (HOWL).

Which stock has performed better over the past year, HOWL or HRTX?

HOWL returned +8.43% over the past 12 months, compared with -76.18% for HRTX (price return, excluding dividends). Past performance does not predict future results.

Are Werewolf Therapeutics and Heron Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons